Word abonnee en neem Beursduivel Premium
Aandeel

Celyad BE0974260896

Laatste koers (eur)

0,326
  • Verschill

    -0,009 -2,54%
  • Volume

    2.604 Gem. (3M) 25,1K
  • Bied

    0,309  
  • Laat

    0,331  
+ Toevoegen aan watchlist

celyad 2020

3.398 Posts
Pagina: «« 1 ... 68 69 70 71 72 ... 170 »» | Laatste | Omlaag ↓
  1. Speedbul 23 februari 2020 12:45
    @Twin. For the DEPLETHINK trial, 2 new centres in Belgium have been added (Antwerp and Brugge) and 1 US center has changed status from "not yet recruiting" to "recruiting".
    So in total we have 8 centres out of which 4 are "recruiting" in the US and 4 sites in Belgium (2 are "recruiting" and the 2 new ones are "not yet recruiting").
    The total anticipated number of patients is 52 out of which 9 patients (6 with dose 1 and 3 with dose 2) USING THE mAb MANUFACTURING PROCESS were enrolled at the time of the meeting "meet the management" from 8/1/2020. The comments from Frédéric Lehmann during the presentation = "the results are not very encouraging" with the mAb manufacturing process..
    Since then (July 2019), Celyad received the green light to use the OPTIMAB MANUFACTURING PROCESS which will be used for all new patients: 3 other patients at dose 2 and all patients at dose 3.
    Now that Celyad is extending the number of trial centers to 8 may suggest that the OptimAb process is boosting the performance.
    One billion cells per infusion cohort to begin in Q1 2020 - autologous + preconditionning + OptimAb process with CYAD-01
  2. Speedbul 23 februari 2020 16:39
    Hi Twin, I believe so.... and we should know more on Tuesday evening through the following webcast

    9th Annual SVB Leerink Global Healthcare Conference
    Date: Tuesday, February 25, 2020
    Presentation time: 3:30 p.m. ET
    Location: New York
  3. uw4ever 24 februari 2020 09:50
    The comments from Frédéric Lehmann during the presentation = "the results are not very encouraging
    Lijkt me toch niet positief?
  4. forum rang 4 Wittman 24 februari 2020 10:09
    quote:

    uw4ever schreef op 24 februari 2020 09:50:

    The comments from Frédéric Lehmann during the presentation = "the results are not very encouraging
    Lijkt me toch niet positief?
    Graag de daaropvolgende zin ook meenemen in de context: "Since then (July 2019), Celyad received the green light to use the OPTIMAB MANUFACTURING PROCESS which will be used for all new patients: 3 other patients at dose 2 and all patients at dose 3. Now that Celyad is extending the number of trial centers to 8 may suggest that the OptimAb process is boosting the performance."
  5. Speedbul 24 februari 2020 10:32
    The results of Deplethink with the mAb manufacturing Process were not very encouraging COMPARING to the THINK STUDY(without preconditionning); meaning that it seem's that the preconditionning was not adding much value.
    Now with the use of the OptimAb Manufacturing process, it may be another story...
  6. Speedbul 24 februari 2020 10:37
    Remember that ARMISTICE has still 300.000 shares as shortsell.
    By looking at this morning's volume, Armistice may be active today
  7. forum rang 4 Wittman 24 februari 2020 11:43
    quote:

    Speedbul schreef op 24 februari 2020 10:37:

    Remember that ARMISTICE has still 300.000 shares as shortsell.
    By looking at this morning's volume, Armistice may be active today
    Agreed – although I don't see one reason why they (Armistice) should have any more insights or knowledge than all other investors combined.
  8. twopence 24 februari 2020 13:10
    Zit pas in phase 1 Twin heeft toch nog wat tijd nodig. Ik zit zelf ook al op heel veel hopen en begin nu toch wel naar positief resultaat te verlangen. :-))
  9. [verwijderd] 24 februari 2020 13:22
    @2pence misschien morgen nieuws van de conferentie? Eens goed nieuws, de echte doorbraken en geen verwachtingen , dat zou ons deugd doen
3.398 Posts
Pagina: «« 1 ... 68 69 70 71 72 ... 170 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in
Premium

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van BeursDuivel en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 55% korting!

Macro & Bedrijfsagenda

  1. 19 april

    1. Japan inflatie maart 2,7% YoY volitaliteit verwacht
    2. WDP Q1-cijfers
    3. EU producentenprijzen maart
    4. VK detailhandelsverkopen maart
    5. Fra ondernemersvertrouwen april
    6. KPN €0,098 ex-dividend
    7. CM.com jaarvergadering
    8. NSI jaarvergadering
    9. American Express Q1-cijfers
  2. 22 april

    1. NL investeringen februari
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht